Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of PARP-inhibitor, Lynparza (olaparib), in combination with abiraterone for patients with mCRPC

Ticker(s): AZN, JNJ, SUNPHARMA.XBOM

Who's the expert?

Institution: Providence Saint Joseph Health

Board certified Medical Oncologist at Providence Saint Joseph Health & member of the Cancer Commitee at Henry Mayo Hospital.
Manages 36 patients with metastatic castration-resistant prostate cancer.
Over 20 years of experience and serves as a member of hospital's P&T committee,

Interview Goal

This conversation will focus on the potential Lynparza in patients with metastatic castration-resistant prostate cancer and looking at the results from the Phase 3 PROpel study of olaparib in combination with abiraterone for patients with mCRPC.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.